Text Size
171 studies found for:    Amyloidosis

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Unknown † A Trial for Systemic Light-chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: BMDex
22 Unknown † A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: Lenalidomide
23 Completed Radioimmunoimaging of AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
24 Recruiting Radioimmunoimaging of AL Amyloidosis
Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
25 Unknown † Safety, Efficacy and Pharmacokinetics of Doxycycline Plus Tauroursodeoxycholic Acid in Transthyretin Amyloidosis
Condition: Transthyretin Amyloidosis
Intervention: Drug: Doxycycline + Tauroursodeoxycholic acid
26 Recruiting Radioimmunoimaging of Light Chain (AL) Amyloidosis
Condition: AL Amyloidosis
Intervention: Biological: Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
27 Recruiting Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)
Conditions: Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention: Other: None. Observational Study.
28 Not yet recruiting Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir and C-11 PiB Positron Emission Tomography
Condition: Cardiac Amyloidosis
Intervention: Drug: F-18 florbetapir and C-11PiB PET
29 Recruiting Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Condition: Primary Systemic Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
30 Recruiting Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
31 Completed
Has Results 		The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis
Condition: Transthyretin-associated Amyloidosis With Polyneuropathy
Intervention: Drug: Fx-1006A
32 Not yet recruiting Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
Conditions: Amyloidosis; Heart (Manifestation);   Senile Cardiac Amyloidosis
Intervention: Drug: Tauroursodeoxycholic Acid and Doxycycline
33 Recruiting High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Device: High Cut-off Hemodialysis;   Drug: Chemotherapy
34 Recruiting Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Intervention: Drug: Pomalidomide and Dexamethasone
35 Completed Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
Condition: Primary Systemic Amyloidosis (AL)
Interventions: Drug: Melphalan;   Drug: Dexamethasone;   Procedure: Autologous stem cell transplantation
36 Recruiting Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
Condition: Primary Amyloidosis of Light Chain Type
Interventions: Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias);   Drug: Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
37 Completed Autologous Stem Cell Rescue for Primary Amyloidosis
Conditions: Amyloidosis;   Blood and Marrow Transplant (BMT)
Intervention: Procedure: high dose chemo then auto hematopoietic cell transplant
38 Active, not recruiting A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Conditions: Leukemia;   Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
39 Completed Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis
Condition: Amyloidosis
Intervention: Drug: CC-5013
40 Completed
Has Results 		Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
Condition: Amyloidosis
Intervention: Drug: VELCADE
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years